Figure 2.
Combination of venetoclax and ibrutinib decreases T-cell compartment skewing and acts on BIM regulation in CLL cells from a Tcl1 mouse model (A) Quantification of the ratio of CD4/CD8 T cells in the different arms of the experiment. Means of CD4/CD8 T-cell ratio ± standard error of the mean (SEM) are presented; significant differences were determined by a 2-way analysis of variance (ANOVA) with Tukey’s multiple-comparisons test. *P < .05, **P < .01 ****P < .0001. (B) Percentages of phenotypes (naive, central memory, effector memory, and double negative) from CD4+ and CD8+ T cells based on CD44 and CD62L expression are presented as means ± SEM. Significant differences were determined by 2-way ANOVA with Tukey’s multiple-comparisons test. *P < .05; **P < .01; ***P < .001; ****P < .0001. (C) Western blot analysis of sorted Tcl1 PBMC leukemia cells at time of relapse. Actin protein is presented as the loading control.

Combination of venetoclax and ibrutinib decreases T-cell compartment skewing and acts on BIM regulation in CLL cells from a Tcl1 mouse model (A) Quantification of the ratio of CD4/CD8 T cells in the different arms of the experiment. Means of CD4/CD8 T-cell ratio ± standard error of the mean (SEM) are presented; significant differences were determined by a 2-way analysis of variance (ANOVA) with Tukey’s multiple-comparisons test. *P < .05, **P < .01 ****P < .0001. (B) Percentages of phenotypes (naive, central memory, effector memory, and double negative) from CD4+ and CD8+ T cells based on CD44 and CD62L expression are presented as means ± SEM. Significant differences were determined by 2-way ANOVA with Tukey’s multiple-comparisons test. *P < .05; **P < .01; ***P < .001; ****P < .0001. (C) Western blot analysis of sorted Tcl1 PBMC leukemia cells at time of relapse. Actin protein is presented as the loading control.

Close Modal

or Create an Account

Close Modal
Close Modal